Type 2 Myocardial InfarctionATTEND-CRNCT07485491
Enhancing Cardiac Rehabilitation Attendance After Secondary Myocardial Infarction Through Clinician Messaging and Motivational Calls
A study testing Clinician-level intervention and Patient-level intervention in people with Type 2 Myocardial Infarction, run by Massachusetts General Hospital at 1 site in United States.
Trial summary
The goal of this clinical trial is to determine if a behavioral intervention can increase attendance at cardiac rehabilitation (CR) after secondary/type 2 myocardial infarction in adult patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Type 2 Myocardial Infarction
- What is being tested?
- Clinician-level intervention and Patient-level intervention
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteUnited States
- Study dates
- Oct 2026to Apr 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years
- Inpatient at MGH with an index likely or confirmed secondary MI
- Primary care provider (PCP) within the Mass General Brigham (MGB) network with at least one visit in the past 2 years
- Anticipated ability to ambulate independently without walking aids or supplemental ambulatory oxygen at discharge
- Ability to provide informed consent
Who cannot join
- Known severe untreated valvular heart disease or severe prosthetic valve dysfunction
- Known hypertrophic obstructive cardiomyopathy
- End-stage heart failure (VAD, transplant patient, or undergoing evaluation for VAD or transplant)
- Hemodynamic instability at the time of pre-screening
- Terminal illness with life expectancy < 1 year
- Severe anemia (hemoglobin < 8 g/dL) at the time of pre-screening
Show all 20Show fewer
- Active, unstable cancer (excluding non-metastatic skin cancer) or currently receiving intensive cancer therapy
- Advanced kidney disease requiring renal replacement therapy
- Receiving palliative or comfort care only
- Recurrent falls (≥2) or falls with injury in the past year
- Physical or cognitive impairment likely to prevent safe participation in exercise over the next 5 months (e.g., significant stroke deficits, dementia)
- High-risk for non-adherence to study requirements
- Incarcerated individuals
- Currently pregnant or within 3 months postpartum
- Previously referred to or participated in CR within the past year
- Alternative MI subtype (spontaneous [type 1 MI] or procedural MI [type 4 or 5 MI]) in the past 6 months
- Suspected or confirmed coronary mechanism of index MI (vasospasm, embolism, or spontaneous coronary artery dissection)
- Anticipated discharge or discharged before enrollment measures can be completed
- Anticipated discharge to a facility where independent participation in CR is not feasible
- Previously enrolled in or declined participation in this study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Massachusetts General Hospital
Boston, Massachusetts, 02114
Cian McCarthy, MB, BCh, BAO, 617-726-2000, CMCCARTHY37@MGB.ORG
Connor Suscha, BS, 617-643-2130, csuscha@mgh.harvard.edu
About this study
Official title: Activating Teams and Patients to Enhance Attendance at Cardiac Rehabilitation After Secondary Myocardial Infarction (ATTEND-CR) Trial
The goal of this clinical trial is to determine if a behavioral intervention can increase attendance at cardiac rehabilitation (CR) after secondary/type 2 myocardial infarction in adult patients. The main question it aims to answer is:
- Does the ATTEND-CR intervention increase attendance at ≥1 CR exercise session within 140 days of randomization?
- Does the intervention increase completion of ≥12 CR exercise sessions within 140 days of randomization?
Read more
Researchers will compare participants receiving the ATTEND-CR intervention (clinician notifications and a motivational interviewing participant phone call) to usual care to see if attendance and completion of CR improve.
Participants:
- Clinicians will receive informational messaging regarding CR and the referral process
- Participate in a motivational interviewing phone call (intervention group only)
- Have follow-up assessments via telephone and electronic health record (EHR) review to track CR attendance, clinical events, and health outcomes
Read the detailed description
The ATTEND-CR trial ("Activating Teams and Patients to Enhance Attendance at Cardiac Rehabilitation After Secondary Myocardial Infarction") is a single-center pilot randomized clinical trial designed to evaluate strategies to increase participation in cardiac rehabilitation (CR) among patients hospitalized with secondary/type 2 (demand/supply mismatch) myocardial infarction (MI). Although CR has been demonstrated to improve functional capacity, quality of life, and cardiovascular outcomes after acute MI, participation rates remain low, particularly in patients with secondary/type 2 MI. This study tests whether a low-risk, behavioral intervention can improve attendance in CR programs.
Participants are randomized to either the ATTEND-CR intervention or usual care. The intervention consists of informational messaging to clinicians regarding CR and the referral process, combined with a follow-up phone call to the patient applying principles of motivational interviewing to support their attendance at CR. Usual care participants receive standard post-MI management without study-driven notifications or motivational support.
Participants are followed for 140 days post-randomization. Study procedures include remote follow-up calls and review of electronic health records to capture participation in CR, clinical events, medication use, and patient-reported health status. The study team monitors safety throughout the trial, focusing on adverse events occurring during or shortly after CR sessions and any serious adverse events that arise during the follow-up period.
- Conditions
- Type 2 Myocardial Infarction
- Being tested
- Clinician-level intervention, Patient-level intervention
- Keywords
- Type 2 myocardial infarction, Secondary myocardial infarction, Cardiac Rehabilitation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Clinician-level interventionBehavioural
The inpatient clinical team receives an EPIC in-basket and email detailing the patient's study participation, benefits of cardiac rehabilitation, and guidance on how to place a cardiac referral if appropriate.
If a cardiac rehabilitation referral is not placed within 3 days post-discharge, a follow-up message is sent to one of the patient's outpatient clinician within 4-28 days post-discharge and within 140 days of randomization.
Patient-level interventionBehavioural
Participants receive a phone call applying motivational interviewing principles if a cardiac rehabilitation referral has been placed by their clinical team within 56 days post-discharge and within 140 days of randomization.
The phone call aims to discuss cardiac rehabilitation, barriers to participation, and support engagement in cardiac rehabilitation.
| Study group | Role | What they receive |
|---|---|---|
| Intervention Arm (ATTEND-CR): | Experimental | Participants clinicians receive an informational message about cardiac rehabilitation and the cardiac rehabilitation referral process. Participants who are referred to cardiac rehabilitation receive a phone call post-discharge applying principles of motivational interviewing. The goal is to encourage cardiac rehabilitation attendance. Receives: Behavioral: Clinician-level intervention; Behavioral: Patient-level intervention |
| Usual Care Arm | No intervention | Participants receive standard post-MI care without clinician informative messaging or a motivational interviewing phone call from the study team. They may still be referred to and attend CR based on usual clinical practice. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants Who Attended one or more Cardiac Rehabilitation Exercise Session
Attendance at one or more cardiac rehabilitation exercise session
Measured: Within 140 days (inclusive) post-randomization
Secondary outcomes (3)
Number of Participants With a Cardiac Rehabilitation Referral
Referral to a cardiac rehabilitation program
Measured: Within 140 days (inclusive) post-randomization
Number of Participants who Completed Cardiac Rehabilitation
Completion defined as attendance at ≥12 cardiac rehabilitation exercise sessions
Measured: Within 140 days (inclusive) post-randomization
Feasibility indicators
- Recruitment: Proportion of eligible patients randomized; threshold ≥40%.
- Retention: Proportion completing interim or final follow-up; threshold ≥70%.
Measured: Recruitment Time Frame: Through completion of enrollment, an average of 18 months. Retention Time Frame: Through completion of participant follow-up, an average of 20 weeks.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Mar 2026
- Study startOct 2026 (estimated)
- Primary completionApr 2028 (estimated)
- Study completionApr 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Type 2 Myocardial InfarctionStudies of the same condition, open and under way.
- More trials run by Massachusetts General HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Massachusetts General Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- Responsible party
- Principal investigator, McCarthy, Cian, Massachusetts General Hospital
- Investigators
- Cian P McCarthy, MB, BCh, BAO, SM, Principal investigator, Massachusetts General Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07485491
- Sponsor's protocol ID
- 2026P000632
- Other IDs
- 5K23HL167659
- Acronym
- ATTEND-CR
- Status last verified
- Sep 2026
- First submitted
- 12 Mar 2026
- Last updated
- 23 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified data generated from this study will be submitted to a data repository in accordance with NIH data sharing guidelines.
Study at a glance
From the registry record, last updated by the sponsor on 23 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Activating Teams and Patients to Enhance Attendance at Cardiac Rehabilitation After Secondary Myocardial Infarction (ATTEND-CR) Trial
- ClinicalTrials.gov ID
- NCT07485491
- Acronym / sponsor ID
- ATTEND-CR / 2026P000632
- Conditions
- Type 2 Myocardial Infarction
- Keywords
- Type 2 myocardial infarction, Secondary myocardial infarction, Cardiac Rehabilitation
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Massachusetts General HospitalUniversity, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- Study start
- Oct 2026 (estimated)
- Primary completion
- Apr 2028 (estimated)
- Study completion
- Apr 2028 (estimated)
- First posted
- 20 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to determine if a behavioral intervention can increase attendance at cardiac rehabilitation (CR) after secondary/type 2 myocardial infarction in adult patients. The main question it aims to answer is:
- Does the ATTEND-CR intervention increase attendance at ≥1 CR exercise session within 140 days of randomization?
- Does the intervention increase completion of ≥12 CR exercise sessions within 140 days of randomization?
Researchers will compare participants receiving the ATTEND-CR intervention (clinician notifications and a motivational interviewing participant phone call) to usual care to see if attendance and completion of CR improve.
Participants:
- Clinicians will receive informational messaging regarding CR and the referral process
- Participate in a motivational interviewing phone call (intervention group only)
- Have follow-up assessments via telephone and electronic health record (EHR) review to track CR attendance, clinical events, and health outcomes
Detailed description
The ATTEND-CR trial ("Activating Teams and Patients to Enhance Attendance at Cardiac Rehabilitation After Secondary Myocardial Infarction") is a single-center pilot randomized clinical trial designed to evaluate strategies to increase participation in cardiac rehabilitation (CR) among patients hospitalized with secondary/type 2 (demand/supply mismatch) myocardial infarction (MI). Although CR has been demonstrated to improve functional capacity, quality of life, and cardiovascular outcomes after acute MI, participation rates remain low, particularly in patients with secondary/type 2 MI. This study tests whether a low-risk, behavioral intervention can improve attendance in CR programs.
Participants are randomized to either the ATTEND-CR intervention or usual care. The intervention consists of informational messaging to clinicians regarding CR and the referral process, combined with a follow-up phone call to the patient applying principles of motivational interviewing to support their attendance at CR. Usual care participants receive standard post-MI management without study-driven notifications or motivational support.
Participants are followed for 140 days post-randomization. Study procedures include remote follow-up calls and review of electronic health records to capture participation in CR, clinical events, medication use, and patient-reported health status. The study team monitors safety throughout the trial, focusing on adverse events occurring during or shortly after CR sessions and any serious adverse events that arise during the follow-up period.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention Arm (ATTEND-CR): | Experimental | Behavioral: Clinician-level intervention, Behavioral: Patient-level interventionParticipants clinicians receive an informational message about cardiac rehabilitation and the cardiac rehabilitation referral process. Participants who are referred to cardiac rehabilitation receive a phone call post-discharge applying principles of motivational interviewing. The goal is to encourage cardiac rehabilitation attendance. |
| Usual Care Arm | No intervention | –Participants receive standard post-MI care without clinician informative messaging or a motivational interviewing phone call from the study team. They may still be referred to and attend CR based on usual clinical practice. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age ≥ 18 years
- Inpatient at MGH with an index likely or confirmed secondary MI
- Primary care provider (PCP) within the Mass General Brigham (MGB) network with at least one visit in the past 2 years
- Anticipated ability to ambulate independently without walking aids or supplemental ambulatory oxygen at discharge
- Ability to provide informed consent
Key exclusion criteria (20 listed)
- Known severe untreated valvular heart disease or severe prosthetic valve dysfunction
- Known hypertrophic obstructive cardiomyopathy
- End-stage heart failure (VAD, transplant patient, or undergoing evaluation for VAD or transplant)
- Hemodynamic instability at the time of pre-screening
- Terminal illness with life expectancy < 1 year
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Clinician-level interventionThe inpatient clinical team receives an EPIC in-basket and email detailing the patient's study participation, benefits of cardiac rehabilitation, and guidance on how to place a cardiac referral if appropriate. If a cardiac rehabilitation referral is not placed within 3 days post-discharge, a follow-up message is sent to one of the patient's outpatient clinician within 4-28 days post-discharge and within 140 days of randomization. | Behavioural | Intervention Arm (ATTEND-CR): |
| Patient-level interventionParticipants receive a phone call applying motivational interviewing principles if a cardiac rehabilitation referral has been placed by their clinical team within 56 days post-discharge and within 140 days of randomization. The phone call aims to discuss cardiac rehabilitation, barriers to participation, and support engagement in cardiac rehabilitation. | Behavioural | Intervention Arm (ATTEND-CR): |
Primary outcome
Number of Participants Who Attended one or more Cardiac Rehabilitation Exercise Session
Time frame: Within 140 days (inclusive) post-randomization
Attendance at one or more cardiac rehabilitation exercise session
3 secondary outcomes
Number of Participants With a Cardiac Rehabilitation Referral
Time frame: Within 140 days (inclusive) post-randomization
Number of Participants who Completed Cardiac Rehabilitation
Time frame: Within 140 days (inclusive) post-randomization
Feasibility indicators
Time frame: Recruitment Time Frame: Through completion of enrollment, an average of 18 months. Retention Time Frame: Through completion of participant follow-up, an average of 20 weeks.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Sep 2026.
- Individual participant dataSharing planned: Yes. De-identified data generated from this study will be submitted to a data repository in accordance with NIH data sharing guidelines.
Related trials for Type 2 Myocardial Infarction
Active, not recruitingPhase 3
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Recruiting
NMR Metabolomics-Based Risk Assessment and Stratified Digital Health Interventions in Middle-Aged Adults (PREMAP)
Type 2 Diabetes, Coronary Heart Disease
Active, not recruiting
The Role of 4 Different Consent Approaches on a Pilot Study to Increase Cardiac Rehabilitation Attendance
Ethics, Cardiac Rehabilitation
RecruitingPhase 2
Improving Coronary Vascular Health in Women
HIV-1-infection, Coronary Microvascular Dysfunction
Not yet recruitingObservational study
A Study of Microcirculatory Function in Type 2 Myocardial Infarction (T2MI)
Myocardial Infarction, Coronary Microvascular Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Cian P McCarthy, MB, BCh, BAO, SM principal investigator
Massachusetts General Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Clinician-level intervention and Patient-level intervention in people with Type 2 Myocardial Infarction, run by Massachusetts General Hospital at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 23 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Cian McCarthy, MB, BCh, BAO, SM (617-726-2000, CMCCARTHY37@MGB.ORG), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants Who Attended one or more Cardiac Rehabilitation Exercise Session (time frame: Within 140 days (inclusive) post-randomization). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2026.